Clinical trials: Germ Cell Tumors
Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer
MGC018 With or Without MGA012 in Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of vobramitamab duocarmazine (MGC018) in patients with advanced solid tumors.
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer, Melanoma, Advanced Solid Tumor, Adult
- Trial name
- NCT03729596
- Testing
- vobramitamab duocarmazine
- Where
- 21 sites in United States, Australia and 2 more
- Volunteers
- 143 people
- Sponsor
- MacroGenics
Malignant Melanoma
A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)
This randomized, open-label study evaluated the efficacy, safety and tolerability of vemurafenib (RO5185426) as compared to dacarbazine in previously untreated patients with metastatic melanoma.
- Trial name
- NCT01006980
- Testing
- Vemurafenib, Dacarbazine
- Where
- 111 sites in United States, Australia and 10 more
- Volunteers
- 675 people
- Sponsor
- Hoffmann-La Roche
AML (Acute Myeloid Leukemia), Glioma
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
A open-label drug-drug interaction (DDI) study to evaluate the effects of olutasidenib on the pharmacokinetics (PK) of a CYP450 and OATP1B1 probe substrate cocktail in participants with IDH1 mutation-positive malignancies.
- Conditions
- AML (Acute Myeloid Leukemia), Glioma, Cholangiocarcinoma, Solid Tumor Malignancies
- Trial name
- NCT07486713
- Testing
- Olutasidenib, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Rigel Pharmaceuticals
Non-Small Cell Lung Cancer, Renal Cell Carcinoma
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)
The purpose of this study is to evaluate participant preference for coformulated hyaluronidase/pembrolizumab pembrolizumab (+) berahyaluronidase alfa [MK-3475A] administered subcutaneously (SC) over pembrolizumab [MK-3475]…
- Conditions
- Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma
- Trial name
- NCT06099782
- Testing
- Pembrolizumab (+) Berahyaluronidase alfa, Pembrolizumab
- Where
- 45 sites in United States, Argentina and 8 more
- Volunteers
- 147 people
- Sponsor
- Merck Sharp & Dohme LLC
Melanoma
A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma
The purpose of this study is to assess the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics of two dose levels of RO7247669 in participants with unresectable or metastatic melanoma to select the recommended dose for…
- Trial name
- NCT05419388
- Testing
- RO7247669
- Where
- 22 sites in Australia, Brazil and 8 more
- Volunteers
- 93 people
- Sponsor
- Hoffmann-La Roche
Osteosarcoma, Sarcoma, Ewing's
A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720)
Participants with relapsed osteosarcoma that can be treated with surgery will be randomized to robatumumab administered intravenously (IV) at one of two dose levels.
- Conditions
- Osteosarcoma, Sarcoma, Ewing's, Peripheral Neuroectodermal Tumor
- Trial name
- NCT00617890
- Testing
- robatumumab
- Volunteers
- 219 people
- Sponsor
- Merck Sharp & Dohme LLC
Stage IV Melanoma, Stage III Melanoma
Gene Therapy in Treating Patients With Stage III or Stage IV Melanoma
RATIONALE: Injecting allovectin-7 into a person's melanoma cells may make the body build an immune response that will kill tumor cells.
- Conditions
- Stage IV Melanoma, Stage III Melanoma, Recurrent Melanoma
- Trial name
- NCT00003646
- Testing
- allovectin-7
- Where
- 3 sites in United States
- Volunteers
- 78 people
- Sponsor
- Vical
Locally Advanced Tumor, Metastatic Solid Tissue Tumors
Safety and Efficacy Study of DCVax-Direct in Solid Tumors
The study comprises a Phase I component during which the optimal dose of DCVax-Direct for the treatment of solid tissue tumors will be identified, followed by a Phase II component to determine if the injection of DCVax-Direct…
- Conditions
- Locally Advanced Tumor, Metastatic Solid Tissue Tumors, Liver Cancer, Colorectal Cancer
- Trial name
- NCT01882946
- Testing
- DCVax-Direct
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Northwest Biotherapeutics
Melanoma
Multi-Centre, Retrospective, Open Label Study, to Validate ML-PrediCare by Patients With Melanoma Under 1st and 2nd Lines of Immunotherapy
This is a retrospective, open label study to establish and validate a prediction technology for advanced melanoma patients under the 1st, 2nd and later treatment lines, with the immunotherapeutic drugs Ipilimumab, Pembrolizumab…
- Trial name
- NCT02581228
- Testing
- ML-PrediCare
- Where
- Israel
- Volunteers
- 500 people
- Sponsor
- Optimata Ltd.
Recurrent Glioblastoma Multiforme
Phase 2 Study of Panzem Nanocrystal Colloidal Dispersion (NCD) in Combination With Fixed-Dose Temozolomide to Patients With Recurrent Glioblastoma Multiforme (GBM)
The purpose of this study is to evaluate the anti-tumor activity and safety of Panzem NCD given in combination with daily oral fixed-dose temozolomide in patients with recurrent glioblastoma multiforme.
- Trial name
- NCT00481455
- Testing
- Panzem NCD, Temozolomide
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- CASI pharmaceuticals, Inc.
Melanoma (Skin)
Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma
RATIONALE: Vaccines made from a person's melanoma cells may make the body build an immune response to kill tumor cells. Interferon alfa may interfere with the growth of the cancer cells.
- Trial name
- NCT00003715
- Testing
- BCG vaccine, autologous tumor cell vaccine, recombinant interferon alfa
- Where
- 17 sites in United States
- Volunteers
- 425 people
- Sponsor
- AVAX Technologies
Melanoma
Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma
The purpose of this Cohort Treatment Plan is to allow access to trametinib (monotherapy or in combination) and dabrafenib (monotherapy or in combination) for eligible patients diagnosed with metastatic melanoma BRAF…
- Trial name
- NCT04489433
- Testing
- Dabrafenib and Trametinib, Dabrafenib, Trametinib
- Sponsor
- Novartis Pharmaceuticals
Solid Tumor, Adult
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
This is a Phase 1 dose-finding study of FT538 in combination with monoclonal antibodies.
- Trial name
- NCT05069935
- Testing
- FT538, Cyclophosphamide, Fludarabine
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- Fate Therapeutics
Pheochromocytoma, Paraganglioma
Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma
The purpose of this sub-study is to provide expanded access of AZEDRA (Ultratrace Iobenguane I 131) and to evaluate the safety and tolerability of AZEDRA in subjects with iobenguane-avid malignant and/or recurrent…
- Trial name
- NCT02961491
- Testing
- Ultratrace Iobenguane I131
- Where
- 3 sites in United States
- Sponsor
- Molecular Insight Pharmaceuticals, Inc.
Melanoma (Skin)
Studying Genes to Identify Melanoma in Patients in Iceland and Their Family Members
RATIONALE: Studying the genes expressed in samples of blood from patients with cancer and their family members may help doctors identify biomarkers related to cancer.
- Trial name
- NCT00346008
- Testing
- mutation analysis, high performance liquid chromatography, laboratory biomarker analysis
- Where
- Iceland
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- Iceland Genomics Corporation
Gastro-enteropancreatic Neuroendocrine Tumor
A Study of Peptide Receptor Radionuclide Therapy (PRRT) Use in Neuroendocrine Tumor (NET) Patients in Germany
The aim of this study was to assess patient characteristics and treatment patterns of gastro-enteropancreatic neuroendocrine tumor (GEP-NET) patients who received PRRT in German routine care.
- Trial name
- LUNET-2 (NCT07653126)
- Where
- 7 sites in Germany
- Volunteers
- 117 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Melanoma
A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma
A Phase 3 comparison of ipilimumab with and without IMO-2125 in advanced melanoma
- Trial name
- NCT03445533
- Testing
- Ipilimumab, Tilsotolimod with Ipilimumab
- Where
- 80 sites in United States, Australia and 9 more
- Volunteers
- 481 people
- Sponsor
- Idera Pharmaceuticals, Inc.
Advanced or Metastatic Merkel Cell Carcinoma, Advanced or Metastatic Cutaneous Squamous Cell Carcinoma
Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors
This is a phase 1b/2, open-label, two-part, multicenter trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of intratumoral cavrotolimod injections alone and in…
- Conditions
- Advanced or Metastatic Merkel Cell Carcinoma, Advanced or Metastatic Cutaneous Squamous Cell Carcinoma, Advanced or Metastatic Melanoma, Advanced or Metastatic Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT03684785
- Testing
- Cavrotolimod, Pembrolizumab, Cemiplimab
- Where
- 26 sites in United States
- Volunteers
- 57 people
- Sponsor
- Exicure, Inc.
Sarcoma, Carcinoma
A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors
20 participants are expected to be enrolled for this open，Single-armed clinical trial to evaluate the safety and efficacy of the recombinant herpes simplex virus Ⅰ, R130 in patients with advanced solid tumors.
- Conditions
- Sarcoma, Carcinoma, Digestive Cancer, Breast Cancer
- Trial name
- NCT05961111
- Testing
- Recombinant oncolytic herpes simplex virus type 1 (R130)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Yunying Medical Technology
Melanoma
A Phase II, Multi-Center, Open-Label, Uncontrolled Study to Evaluate the Efficacy and Safety of Sorafenib Given Daily in Combination With Repeated 21-Day Cycles of Dacarbazine (DTIC) Chemotherapy in Subjects With Advanced Metastatic Melanoma
The purpose of this study is to see whether a new type of anti-cancer drug, known as BAY 43-9006, can be given safely and with good effect in combination with dacarbazine (DTIC).
- Trial name
- NCT00492297
- Testing
- Sorafenib (Nexavar, BAY43-9006) + Dacarbazine (DTIC)
- Where
- 12 sites in France, United Kingdom
- Volunteers
- 83 people
- Sponsor
- Bayer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.